Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

aHUS

Roche Basel Switzerland

US, EU regulators start review of Roche’s Soliris rival satralizumab

Sets up a possible market clash with Alexion next year

- PMLiVE

Alexion eyes Soliris combo with $930m deal to buy Achillion

Additional shares will be tied to various milestones

Roche Basel Switzerland

Roche presents new data in NMOSD, could challenge Alexion’s Soliris

Reduced risk of relapse by 55%

- PMLiVE

Medimmune-born Viela files $150m IPO, eyes first product launch

Funds will help to push a number of pipeline candidates

- PMLiVE

Amgen takes aim at Alexion’s patents for Soliris

Follows extension of Soliris patent protection until 2027

- PMLiVE

Alexion’s Soliris adds new approval in rare disease NMOSD

First ever drug approved for rare autoimmune disease

- PMLiVE

Krystal Bio preps pivotal trials for rare skin disease gene therapy

Encouraging results for patients

- PMLiVE

CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

Opioid dependence therapy and Pfizer's PARP inhibitor also recommended

- PMLiVE

Rare Diseases Day

More than other conditions, rare diseases require a human touch, but technology can provide a vital helping hand

Statistics and Infographics for Rare Disease Day

Rare Disease Day 2019

Today is #RareDiseaseDay and is an opportunity to highlight some truly unbelievable/frightening statistics around rare diseases.

Cuttsy + Cuttsy

- PMLiVE

Alexion targets RNAi with $637m Dicerna deal

Bolsters pipeline ahead of Soliris patent protection loss

- PMLiVE

Encouraging data for GenSight’s blinding retinal disease gene therapy

Better results after April's setback

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links